PDCD1 and renal carcinoma: Entinostat, a selective class I histone deacetylation inhibitor, significantly inhibited the immunosuppressive function of MDSCs and Treg infiltration in TME in a mouse model of renal cancer, thereby enhancing the efficacy of PD‐1 mAbs.